Jørgen Søberg Petersen

Jørgen Søberg Petersen is a highly experienced leader in the pharmaceutical and biotechnology sectors, currently serving as a Senior Partner at Novo Holdings since September 2017. In addition to this role, Jørgen holds several non-executive director positions across multiple companies, including Breye Therapeutics, Engimmune Therapeutics, Hemab, Tribune Therapeutics, and previously Amolyt Pharma and VectivBio AG. Notably, Jørgen has been instrumental in founding and investing in innovative companies targeting significant medical needs, such as therapies for diabetic retinopathy, TCR-based treatments, and rare bleeding disorders. Jørgen's academic credentials include an M.D. and a Ph.D. in Pharmacology from the University of Copenhagen, complemented by multiple executive training qualifications from prestigious institutions like INSEAD and Northwestern University.